These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22872803)

  • 1. The role of regulated clinical trials in the development of bacteriophage therapeutics.
    Parracho HM; Burrowes BH; Enright MC; McConville ML; Harper DR
    J Mol Genet Med; 2012; 6():279-86. PubMed ID: 22872803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.
    Kulshrestha M; Tiwari M; Tiwari V
    Microb Pathog; 2024 Jan; 186():106467. PubMed ID: 38036110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
    Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
    Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.
    Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic Guidelines for Bacteriophage Isolation and Characterization.
    Samir S
    Recent Pat Biotechnol; 2023; 17(4):312-331. PubMed ID: 36263478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic bacteriophages as a rescue treatment for drug-resistant infections - an in vivo studies overview.
    Kwiatek M; Parasion S; Nakonieczna A
    J Appl Microbiol; 2020 Apr; 128(4):985-1002. PubMed ID: 31778593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational research priorities for bacteriophage therapeutics.
    Schooley RT
    Essays Biochem; 2024 Oct; ():. PubMed ID: 39417290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
    Furfaro LL; Payne MS; Chang BJ
    Front Cell Infect Microbiol; 2018; 8():376. PubMed ID: 30406049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage therapy: delivering on the promise.
    Harper DR; Anderson J; Enright MC
    Ther Deliv; 2011 Jul; 2(7):935-47. PubMed ID: 22833904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.
    Łobocka M; Dąbrowska K; Górski A
    BioDrugs; 2021 May; 35(3):255-280. PubMed ID: 33881767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage Therapy in Germany-Update 2023.
    Willy C; Bugert JJ; Classen AY; Deng L; Düchting A; Gross J; Hammerl JA; Korf IHE; Kühn C; Lieberknecht-Jouy S; Rohde C; Rupp M; Vehreschild MJGT; Vogele K; Wienecke S; Witzenrath M; Würstle S; Ziehr H; Moelling K; Broecker F
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards Inhaled Phage Therapy in Western Europe.
    Wienhold SM; Lienau J; Witzenrath M
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards promising antimicrobial alternatives: The future of bacteriophage research and development in Saudi Arabia.
    Alsaadi A; Imam M; Alghamdi AA; Alghoribi MF
    J Infect Public Health; 2022 Dec; 15(12):1355-1362. PubMed ID: 36332378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.
    Bodier-Montagutelli E; Morello E; L'Hostis G; Guillon A; Dalloneau E; Respaud R; Pallaoro N; Blois H; Vecellio L; Gabard J; Heuzé-Vourc'h N
    Expert Opin Drug Deliv; 2017 Aug; 14(8):959-972. PubMed ID: 27776446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.